Expertise in
1
conditions

Dr. Rizwana Mohseni

Family Medicine
Health And Wellness Center Inc.
23672 Birtcher Dr Unit Aa, 
Lake Forest, CA 
Expertise in
1
conditions
Health And Wellness Center Inc.
23672 Birtcher Dr Unit Aa, 
Lake Forest, CA 

Overview

Rizwana Mohseni is a primary care provider, practicing in Family Medicine in Lake Forest, California.

Dr. Mohseni is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Maturity Onset Diabetes of the Young, Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes (T2D), and Severe Acute Respiratory Syndrome (SARS).

She is actively involved in clinical research, co-authoring 7 peer reviewed articles and participating in 26 clinical trials.

Specialties

Family Medicine

Licenses

Family Medicine in CA

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Health and Wellness Center Inc.
23672 Birtcher Dr Unit Aa, Lake Forest, CA 92630

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared With Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes
A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared With Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes
Enrollment Status: Active_not_recruiting
Publish Date: December 12, 2025
Intervention Type: Drug
Study Phase: Phase 4
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Enrollment Status: Completed
Publish Date: July 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve Adults With Type 2 Diabetes
A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve Adults With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: May 16, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 2
A Phase 2, Prospective, Multicenter, Double-blind, Randomized Study of Saroglitazar Magnesium 1 mg, 2 mg or 4 mg Versus Placebo in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis
A Phase 2, Prospective, Multicenter, Double-blind, Randomized Study of Saroglitazar Magnesium 1 mg, 2 mg or 4 mg Versus Placebo in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: October 24, 2024
Intervention Type: Drug
Study Phase: Phase 2
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
Enrollment Status: Completed
Publish Date: May 16, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab
Study Phase: Phase 2/Phase 3
Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)
Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)
Enrollment Status: Completed
Publish Date: April 08, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
View 9 Less Clinical Trials

7 Total Publications

Oral Insulin Alleviates Liver Fibrosis and Reduces Liver Steatosis in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes: Results of Phase II Randomized, Placebo-controlled Feasibility Clinical Trial.
Oral Insulin Alleviates Liver Fibrosis and Reduces Liver Steatosis in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes: Results of Phase II Randomized, Placebo-controlled Feasibility Clinical Trial.
Journal: Gastro hep advances
Published: October 03, 2023
Similar Doctors
Expertise in
8
conditions
Dr. Marc Richmond
Family Medicine
Expertise in
8
conditions
Dr. Marc Richmond
Family Medicine

Office

5502 Southall Ter, 
Irvine, CA 
 (5.9 miles away)
949-466-4651
Languages Spoken:
English
See accepted insurances

Marc Richmond is a primary care provider, practicing in Family Medicine in Irvine, California. Dr. Richmond is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Pediatric Myocarditis, Cardiomyopathy, Myocarditis, Heart Transplant, and Lung Transplant.

Expertise in
9
conditions
Dr. Joshua J. Solomon
Family Medicine
Expertise in
9
conditions
Dr. Joshua J. Solomon
Family Medicine

Playa Vista Medical Offices

5300 Mcconnell Ave, 
Los Angeles, CA 
 (46.9 miles away)
833-574-2273
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Joshua Solomon is a primary care provider, practicing in Family Medicine in Los Angeles, California. Dr. Solomon is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Rheumatoid Lung Disease, Interstitial Lung Disease, Acute Interstitial Pneumonia, Pulmonary Fibrosis, and Endoscopy. Dr. Solomon is currently accepting new patients.

Expertise in
22
conditions
Dr. Ashish Bhalla
Family Medicine
Expertise in
22
conditions
Dr. Ashish Bhalla
Family Medicine

Office

3110 Chino Ave Ste 150B, 
Chino Hills, CA 
 (22.9 miles away)
909-630-7868
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ashish Bhalla is a primary care provider, practicing in Family Medicine in Chino Hills, California. Dr. Bhalla is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Typhus, Pyomyositis, COVID-19, Thrombectomy, and Kidney Transplant.

Frequently Asked Questions about Dr. Rizwana Mohseni

How do I make an appointment with Dr. Rizwana Mohseni?

You can book an appointment with Dr. Rizwana Mohseni by calling their office at 949-770-7301. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Rizwana Mohseni a top-rated expert for Maturity Onset Diabetes of the Young?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Rizwana Mohseni is classified as an Advanced expert for Maturity Onset Diabetes of the Young, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Rizwana Mohseni specialize in?

While Dr. Rizwana Mohseni is a Family Medicine, they have specific expertise in Maturity Onset Diabetes of the Young, Non-Alcoholic Fatty Liver Disease, and Type 2 Diabetes (T2D). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Family Medicine.

Does Dr. Rizwana Mohseni participate in research or clinical trials?

Yes. Dr. Rizwana Mohseni has published 7 articles and abstracts on conditions like Maturity Onset Diabetes of the Young. You can view a list of Dr. Rizwana Mohseni's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Rizwana Mohseni accept my insurance?

Dr. Rizwana Mohseni accepts most major insurance plans, including Blue Shield of California and Health Net. We recommend calling the office directly at 949-770-7301 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mohseni's expertise for a condition
ConditionClose
      View All 11 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile